Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Opicapone adjuvant for the treatment of idiopathic Parkinson's disease Opicapone (Ongentys) Parkinson's disease Neurology 2023 View  |  Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line Oportuzumab monatox (Vicinium; VB4-845; Proxinium) Bladder cancer Urological Cancer 2020 View  |  Download
Oral Semaglutide for the treatment of type 2 diabetes mellitus Semaglutide (Ozempic) Type 2 diabetes Endocrine Nutritional and Metabolic Disorders 2018 View  |  Download
Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Otilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis Otilimab Rheumatoid arthritis Rheumatology 2022 View  |  Download
OTL-103 for Wiskott-Aldrich syndrome OTL-103 (GSK-2696275) Wiskott-Aldrich syndrome (WAS) Genetic Disorders , Immunology 2020 View  |  Download
OTL-200 for Metachromatic Leukodystrophy OTL-200 (GSK-2696274) Metachromatic leukodystrophy (MLD) Endocrine Nutritional and Metabolic Disorders , Genetic Disorders 2019 View  |  Download
1 2 70 71 72 73 74 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications